表紙
市場調查報告書

裘馨氏肌肉萎縮症(DMD)治療藥的全球市場:2019年∼2023年

Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 910216
出版日期 內容資訊 英文 132 Pages
訂單完成後即時交付
價格
Back to Top
裘馨氏肌肉萎縮症(DMD)治療藥的全球市場:2019年∼2023年 Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023
出版日期: 2019年09月03日內容資訊: 英文 132 Pages
簡介

全球裘馨氏肌肉萎縮症(DMD)治療藥市場上,預計未滿足需求高,策略性聯盟的增加,患者支援計劃等成為成長促進因素,在預測期間內預計將以37%以上的年複合成長率擴大。但,治療費用高,嚴格的法規環境,DMD治療藥的副作用等要素,可能妨礙在預測期間內DMD治療藥產業的成長。

本報告提供全球裘馨氏肌肉萎縮症(DMD)治療藥市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 開發平台

第7章 市場區隔:各類型

  • 市場區隔:各類型
  • 各類型比較:市場規模及預測(2018年∼2023年)
  • 生技藥品
  • 小分子
  • 市場機會:各類型

第8章 客戶形勢

第9章 各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第10章 決策架構

第11章 成長要素與課題

  • 市場成長要素
  • 市場課題

第12章 市場趨勢

  • 強力的開發平台
  • 研究資金的增加
  • 特別藥的指定

第13章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭方案

第14章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • F. Hoffmann-La Roche Ltd.
  • PTC Therapeutics Inc.
  • Santhera Pharmaceuticals
  • Sarepta Therapeutics Inc.
  • Wave Life Sciences Ltd.

第15章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第16章 關於TECHNAVIO

目錄
Product Code: IRTNTR31975

About this market

Technavio's Duchenne muscular dystrophy (DMD) therapeutics market analysis considers sales from both biologics and small molecules in Asia, Europe, North America, and ROW. In 2018, the biologics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as high efficacy to stop the progression of the disease will play a significant role in the biologics segment to maintain its market position. Also, our global DMD therapeutics market report looks at factors such as high unmet need, increasing strategic alliance, and patient assistance programs. However, high treatment costs, stringent regulatory environment, and adverse side effects of DMD therapeutics may hamper the growth of the DMD therapeutics industry over the forecast period.

Overview

High unmet need.

Duchenne muscular dystrophy led to the identification of the dystrophin gene, which is responsible for coding patients that helps in maintaining muscle cell membrane stability. This led to the identification of various therapeutic targets, such as dystrophin-based therapies like EXONDYS 51 and TRANSLARNA. However, the high costs of these drugs are restricting their penetration in many underdeveloped and developing countries. This has resulted in high unmet demand for affordable therapies that can reverse the progression of DMD. This is encouraging many leading vendors to introduce affordable novel therapies for the treatment. The strong distribution network of vendors coupled with the presence of reimbursement policies will lead to the expansion of the global Duchenne muscular dystrophy (DMD) therapeutics market at a CAGR of over 37% during the forecast period.

Increasing research funding

Advances in diagnostic methods is leading researchers and organizations to conduct research onresearch developing therapeutics for treating DMD. For instance, Muscular Dystrophy Association developed an innovative way to fund the research on moving new drug targets into clinical stages at a fast pace. On the other hand, organizations such as Duchenne UK provides research grants to vendors and researchers developing therapeutics for DMD. This increasing research funding is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global Duchenne muscular dystrophy (DMD) therapeutics market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of a few major players, the global Duchenne muscular dystrophy (DMD) therapeutics market is highly concentrated. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading Duchenne muscular dystrophy (DMD) therapeutics manufacturers, that include F. Hoffmann-La Roche Ltd., PTC Therapeutics Inc., Santhera Pharmaceuticals, Sarepta Therapeutics Inc., Wave Life Sciences Ltd.

Also, the Duchenne muscular dystrophy (DMD) therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • The threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Biologics - Market size and forecast 2018-2023
  • Small molecules - Market size and forecast 2018-2023
  • Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-202
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

  • Strong pipeline
  • Increasing research funding
  • Special drug designations

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • F. Hoffmann-La Roche Ltd.
  • PTC Therapeutics Inc.
  • Santhera Pharmaceuticals
  • Sarepta Therapeutics Inc.
  • Wave Life Sciences Ltd.

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 16: EXPLORE TECHNAVIO

LIST OF EXHIBITS:

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Global DMD therapeutics market pipeline: Overview
  • Exhibit 19: Global DMD therapeutics market pipeline: Snapshot
  • Exhibit 20: Type - Market share 2018-2023 (%)
  • Exhibit 21: Comparison by type
  • Exhibit 22: Biologics - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Biologics - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Small molecules - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 25: Small molecules - Year-over-year growth 2019-2023 (%)
  • Exhibit 26: Market opportunity by type
  • Exhibit 27: Customer landscape
  • Exhibit 28: Market share by geography 2018-2023 (%)
  • Exhibit 29: Geographic comparison
  • Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Top 3 countries in North America
  • Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: Top 3 countries in Europe
  • Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: Top 3 countries in Asia
  • Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 41: Top 3 countries in ROW
  • Exhibit 42: Key leading countries
  • Exhibit 43: Market opportunity
  • Exhibit 44: Impact of drivers and challenges
  • Exhibit 45: Vendor landscape
  • Exhibit 46: Landscape disruption
  • Exhibit 47: Vendors covered
  • Exhibit 48: Vendor classification
  • Exhibit 49: Market positioning of vendors
  • Exhibit 50: F. Hoffmann-La Roche Ltd. - Vendor overview
  • Exhibit 51: F. Hoffmann-La Roche Ltd. - Business segments
  • Exhibit 52: F. Hoffmann-La Roche Ltd. - Organizational developments
  • Exhibit 53: F. Hoffmann-La Roche Ltd. - Geographic focus
  • Exhibit 54: F. Hoffmann-La Roche Ltd. - Segment focus
  • Exhibit 55: F. Hoffmann-La Roche Ltd. - Key offerings
  • Exhibit 56: F. Hoffmann-La Roche Ltd. - Key customers
  • Exhibit 57: PTC Therapeutics Inc. - Vendor overview
  • Exhibit 58: PTC Therapeutics Inc. - Business segments
  • Exhibit 59: PTC Therapeutics Inc. - Organizational developments
  • Exhibit 60: PTC Therapeutics Inc. - Key offerings
  • Exhibit 61: PTC Therapeutics Inc. - Key customers
  • Exhibit 62: Santhera Pharmaceuticals - Vendor overview
  • Exhibit 63: Santhera Pharmaceuticals - Business segments
  • Exhibit 64: Santhera Pharmaceuticals - Organizational developments
  • Exhibit 65: Santhera Pharmaceuticals - Geographic focus
  • Exhibit 66: Santhera Pharmaceuticals - Key offerings
  • Exhibit 67: Santhera Pharmaceuticals - Key customers
  • Exhibit 68: Sarepta Therapeutics Inc. - Vendor overview
  • Exhibit 69: Sarepta Therapeutics Inc. - Business segments
  • Exhibit 70: Sarepta Therapeutics Inc. - Organizational developments
  • Exhibit 71: Sarepta Therapeutics Inc. - Geographic focus
  • Exhibit 72: Sarepta Therapeutics Inc. - Key offerings
  • Exhibit 73: Sarepta Therapeutics Inc. - Key customers
  • Exhibit 74: Wave Life Sciences Ltd. - Vendor overview
  • Exhibit 75: Wave Life Sciences Ltd. - Business segments
  • Exhibit 76: Wave Life Sciences Ltd. - Organizational developments
  • Exhibit 77: Wave Life Sciences Ltd. - Key offerings
  • Exhibit 78: Wave Life Sciences Ltd. - Key customers
  • Exhibit 79: Validation techniques employed for market sizing
  • Exhibit 80: Definition of market positioning of vendors
Back to Top